Mora, J., Chan, G. C. F., Morgenstern, D. A., Amoroso, L., Nysom, K., Faber, J., Wingerter, A., Bear, M. K., Rubio-San-Simon, A., Heras, B. M. D. L., Tornøe, K., Düring, M., Kushner, B. H. (2025). The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial. Nature Communications. https://doi.org/10.1038/s41467-025-56619-x